

## **Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma**

**M. Fedders · M. Hartmann · A. Schneider · R. Kath · O. Camara · H. Oelschläger**

Published online: 25 September 2007  
© Springer-Verlag 2007

**Erratum to: J Cancer Res Clin Oncol (2007) 133:619–625  
DOI 10.1007/s00432-007-0210-4**

The original version of this article unfortunately contained a mistake. The order of the authors was incorrect. The correct order of authors is as follows:

Fedders M, Hartmann M, Schneider A, Kath R, Camara O, Oelschläger H.

---

The online version of the original article can be found under  
doi:[10.1007/s00432-007-0210-4](https://doi.org/10.1007/s00432-007-0210-4).

---

M. Fedders (✉)  
Duisburg Hospital, Zu den Rehwiesen 9,  
47055 Duisburg, Germany  
e-mail: [maike.fedders@uni-duisburg-essen.de](mailto:maike.fedders@uni-duisburg-essen.de)

M. Hartmann  
FSU Hospital Pharmacy, Erlanger Allee 101,  
07743 Jena, Germany

A. Schneider  
Hospital for Gynecology and Interdisciplinary Breast Center,  
Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany

R. Kath  
Clinic for Hematology and Oncology, Medical Clinic I,  
Hospitals Essen Nord-West, Hülsmannstrasse 6,  
45355 Essen, Germany

O. Camara  
Hospital for Gynecology FSU Jena,  
Bachstrasse 18, 07740 Jena, Germany

H. Oelschläger  
Institute for Pharmacy FSU Jena,  
Simmelweisstrasse 10, 07743 Jena, Germany